Critical reviews in oncology/hematology · 2025
Survival outcomes with enfortumab vedotin-containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ansab Muhammad, Rath Shree, Ishaque Ghazal, Araib Eiman, Khan Iqra, Alam Umama, Sadiq Zain, Singla Nirmish
Аннотация
BACKGROUND: Metastatic urothelial carcinoma remains a highly lethal disease, particularly following progression on platinum-based chemotherapy and immune checkpoint inhibitors. Enfortumab vedotin (EV), a nectin-4-targeted antibody-drug conjugate, has shown encouraging activity in this setting, both as monotherapy and in combination with other agents.
METHODS: A systematic review and meta-analysis was conducted PubMed, Embase, and the Cochrane Library were searched till March 2025 for original studies reporting survival outcomes of EV-based therapy. Summary survival curves were generated from Kaplan-Meier curves for overall survival and progression-free survival, and median OS and PFS were calculated, along with pooled OS and PFS at different time points. Secondary endpoints included objective response rate (ORR) and incidence of grade ≥ 3 treatment-related adverse events (TRAEs). Subgroup analyses were performed by regimen type (monotherapy vs. combination) and study phase.
RESULTS: 32 studies involving 3770 patients were included. The pooled median OS was 26.7 months with EV plus pembrolizumab and 14.9 months with EV monotherapy. Median PFS was 13.14 and 6.89 months, respectively. The overall pooled ORR was 49 % (95 % CI: 45-53 %), with EV plus pembrolizumab achieving an ORR of 68 % (95 % CI: 64-71 %). 88 % of patients experienced an AE of any grade, with rash, peripheral neuropathy, and fatigue being the most common toxicities.
CONCLUSION: EV-containing regimens demonstrate robust survival benefits and high response rates in patients with metastatic urothelial carcinoma, especially when combined with immune checkpoint blockade. These results support EV's integration into treatment paradigms and highlight the need for confirmatory randomized trials and biomarker-driven strategies to optimize outcomes.
METHODS: A systematic review and meta-analysis was conducted PubMed, Embase, and the Cochrane Library were searched till March 2025 for original studies reporting survival outcomes of EV-based therapy. Summary survival curves were generated from Kaplan-Meier curves for overall survival and progression-free survival, and median OS and PFS were calculated, along with pooled OS and PFS at different time points. Secondary endpoints included objective response rate (ORR) and incidence of grade ≥ 3 treatment-related adverse events (TRAEs). Subgroup analyses were performed by regimen type (monotherapy vs. combination) and study phase.
RESULTS: 32 studies involving 3770 patients were included. The pooled median OS was 26.7 months with EV plus pembrolizumab and 14.9 months with EV monotherapy. Median PFS was 13.14 and 6.89 months, respectively. The overall pooled ORR was 49 % (95 % CI: 45-53 %), with EV plus pembrolizumab achieving an ORR of 68 % (95 % CI: 64-71 %). 88 % of patients experienced an AE of any grade, with rash, peripheral neuropathy, and fatigue being the most common toxicities.
CONCLUSION: EV-containing regimens demonstrate robust survival benefits and high response rates in patients with metastatic urothelial carcinoma, especially when combined with immune checkpoint blockade. These results support EV's integration into treatment paradigms and highlight the need for confirmatory randomized trials and biomarker-driven strategies to optimize outcomes.